Business Wire

Kalray Announces the Availability of Its TURBOCARD4 Card: a Paradigm Shift in Compute Acceleration for Smart Vision and Gen-AI Data-indexing Applications

2.4.2024 19:57:00 EEST | Business Wire | Press release

Share

Kalray (Euronext Growth Paris: ALKAL), a leading provider of hardware and software solutions to accelerate data intensive workflows from Cloud to Edge announces the commercial availability of its latest product, the TURBOCARD4 (TC4) acceleration card. Powered by four of Kalray’s latest generation of DPU processors, the TC4 targets the fast growing markets of AI-powered smart vision and data-indexing applications. The TC4 is manufactured in France, in the French plant of Asteelflash, one of the leading global manufacturers worldwide. Kalray already received an initial order of more than $1 million (hundreds of cards) 1 to be recognized this year.

TC4 TARGETS THE FAST GROWING COMPUTE ACCELERATION CARD MARKET

Whereas enterprises and data centers have to process an ever-growing amount of data, compute acceleration cards are getting more and more traction to bring the best performance and best power efficiency in data processing.

“The availability of our new TC4 acceleration card is a major step for Kalray to set the stage for the widespread adoption of our latest acceleration technology. The TC4 has already been selected by one of our major customers and we envision a fast commercial take-off due to the ever-increasing demand in data processing acceleration solutions”, shares Eric Baissus, Kalray CEO.

“In addition, we are very proud to announce that the TC4 is our first “made in France” product. The production is ramping up rapidly in the plant of the leading global manufacturer AsteelFlash in Langon”.

BUILT TO COMBINE AI AND CLASSICAL COMPUTING

TC4 embodies Kalray's vision in addressing the intricate demands of modern computing workloads. Housing four of the latest generation of Kalray’s DPUs, Coolidge2TM, in a single PCIe card, Kalray’s TC4 is designed to ensure customers can merge classical and AI-based processing technologies and create superior, efficiency-driven systems for the most processing-intensive AI applications. DPUs offer a very complementary architecture to GPUs, allowing for the processing of a large number of different operations in parallel in an asynchronous way. DPUs are well-suited for pre-processing data that is later used by GPUs or in the context of complex intelligent systems running many different algorithms in parallel.

TWO FAST GROWING MARKETS TARGETTED: THE SMART VISION MARKET…

TC4 is strategically targeted at two rapidly growing markets. The first one is the Smart Vision market. Smart vision applications play a pivotal role in transformative sectors such as Industrial, Health Science, or Smart City operations due to their ability to analyze visual data in real-time, make intelligent decisions, and automate complex processes. The smart vision market size was valued at USD 20.31 billion in 2023 which is forecasted to reach USD 175.72 billion by 2032, exhibiting a CAGR of 27.3% ​ (Fortune Business Insights)​. These projections highlight the increasing demand of smart vision technologies across various industries, driven by advancements in AI and machine learning, and their application in automation, quality control, and enhanced operational efficiencies.

…AND THE DATA-INDEXING FOR GEN-AI MARKET

In the context of Generative AI, data indexing is crucial for several reasons. Generative AI models, such as those used in natural language processing or image generation, often need to access enormous datasets. Efficient indexing minimizes the time required to fetch the relevant data, making the training and inference processes faster.

In addition, as Generative AI models become more complex, the datasets they train on grow exponentially. Data indexing allows these models to scale more effectively by ensuring that the increase in data volume does not linearly increase access times.

Data-Indexing also improves models’ outputs accuracy as indexing helps quickly identify the most relevant data pieces to insert in model context and prompt. This ensures that the model's outputs are as accurate and contextually appropriate as possible.

TC4 PRODUCTION HAS BEEN RE-LOCATED TO ASTEELFLASH FRENCH PLANT

Kalray's commitment to quality and desire to re-locate its production to Europe led to the alliance with Asteelflash for TC4 production. Asteelflash is one of the leading global electronic manufacturing services (EMS) companies, specializing in complex and high-tech manufacturing solutions across various industries. Asteelflash has several plants in Europe, including Germany and France. The TC4 production is performed in the Langon, France plant. This partnership has been supported by the French government as part of the CARAIBE funded project. The production volume is expected to grow from a few hundred per month today to several thousands of units per month, starting in 2025.

ABOUT KALRAY
Kalray is a leading provider of hardware and software technologies and solutions for high-performance, data-centric computing markets, from cloud to edge.

Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures. Its offers include its unique patented DPU (Data Processing Unit) processors and acceleration cards as well as its leading-edge software-defined storage and data management offers. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, Media & Entertainment, Life Sciences, Scientific Research, Edge Computing, Automotive and others.

Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com

1 See press release as of 11th January, 2024

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

INVESTOR

E ric BAISSUS
contactinvestisseurs@kalrayinc.com
Phone +33 4 76 18 90 71

ACTUS Finance & Communication
Anne-Pauline PETUREAUX
kalray@actus.fr
Phone + 33 1 53 67 36 72

PRESS

P enta STANLEY
communication@kalrayinc.com
Phone +44 7939 877 880

ACTUS Finance & Communication
Serena BONI
sboni@actus.fr
Phone +33 4 72 18 04 92

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release

VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on

Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release

Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release

Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye